<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778191</url>
  </required_header>
  <id_info>
    <org_study_id>201501099</org_study_id>
    <nct_id>NCT02778191</nct_id>
  </id_info>
  <brief_title>Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concomitant chemoradiotherapy improves overall survival in patients with locally advanced
      head and neck squamous cell carcinoma (LA-HNSCC) compared to radiotherapy alone. Cisplatin
      100 mg/m2 at day 1, 22 and 43 is widely used but results in considerable acute and late
      toxicity. Three cycles of carboplatin plus 5-fluorouracil (5-FU) is an accepted alternative
      but both chemotherapy regimens have not been compared prospectively. The aim of this study
      is to compare tolerability, efficacy, toxicity and quality of life in patients with LA-HNSCC
      treated with concomitant cisplatin and carboplatin plus 5-FU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective comparison of patients with LA-HNSCC treated with chemoradiotherapy
      at 2 tertiary care centers in the Netherlands (UMCG and VUmc), where one center routinely
      gives carboplatin plus 5FU (UMCG) and the other center (VUmc) uses high dose cisplatin as
      standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chemotherapy completion rate</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of patients who completed 3 cycles of chemotherapy between both cohorts will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 acute toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>retrospective data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>retrospective data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>EORTC questionnaire QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>EORTC questionnaire HN35</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concomitant cisplatin</arm_group_label>
    <description>Patients treated with concomitant cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin plus 5-FU</arm_group_label>
    <description>Patients treated with carboplatin plus 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>100 mg/m2 day 1, 22 and 43</description>
    <arm_group_label>Concomitant cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin 300-350 mg/m2 day 1, 22 and 43</description>
    <arm_group_label>Carboplatin plus 5-FU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 600 mg/m2 days 1-4, 22-25 and 43-46</description>
    <arm_group_label>Carboplatin plus 5-FU</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced head and neck squamous cell carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage III-IV LA-HNSCC of hypopharynx, oropharynx, larynx, oral cavity

          -  Primary treatment with concomitant chemoradiotherapy consisting of three-weekly
             cisplatin or carboplatin plus 5-FU

          -  Age â‰¤ 70 years

          -  No previous treatment for head and neck cancer

          -  No distant metastases

        Exclusion Criteria:

          -  Previous treatment for head and neck cancer

          -  Distant metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Oosting, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>S. Oosting, MD, PhD</last_name>
    <phone>+31 50 3612821</phone>
    <email>s.oosting@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>J. Buter, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. F. Oosting, MD, PhD</last_name>
      <phone>+31 50 3612821</phone>
      <email>s.oosting@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>S. F. Oosting, MD, PhD</last_name>
      <phone>+3150 3612821</phone>
      <email>s.oosting@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>S. F. Oosting, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 24, 2016</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>S.F. Oosting</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>5-fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
